Trials / Completed
CompletedNCT00094159
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Pharmacokinetic Profiles of Weekly Intravenous Administrations of SNS-595 in Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Sunesis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether SNS-595 given intravenously weekly for 3 weeks is safe.
Detailed description
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood) and determining the dose and dose schedule for the next phase of studies with SNS-595.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNS-595 |
Timeline
- Start date
- 2004-10-01
- First posted
- 2004-10-15
- Last updated
- 2007-05-10
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00094159. Inclusion in this directory is not an endorsement.